Frezent Biological Solutions

Patients are told they are “cancer-free” only to discover that a few undetectable cancer cells survived initial treatment and they have to face another battle with cancer. Recurrent cancer is frequently more aggressive and resistant to treatments, which for many cancer patients means survival of less than a year. Prevention of recurrence remains an unmet need in oncology and FREZENT’s mission is to address this need for over 30 million cancer survivors worldwide who are currently facing ~50% ...